Rafael Holdings Reports Improved Financial Results and Strategic Progress

Rafael Holdings ( (RFL) ) has released its Q3 earnings. Here is a breakdown of the information Rafael Holdings presented to its investors.

Rafael Holdings, Inc. is a diversified company with interests in clinical and early-stage pharmaceutical ventures, including its wholly owned subsidiary Cyclo Therapeutics, which focuses on developing treatments for rare genetic disorders such as Niemann-Pick Disease Type C1.

In its third quarter fiscal 2025 earnings report, Rafael Holdings highlighted the completion of its merger with Cyclo Therapeutics and the upcoming results from a Phase 3 clinical trial for a potential treatment for Niemann-Pick Disease Type C1. The company also reported a strengthened financial position following a $25 million rights offering.

For the third quarter ended April 30, 2025, Rafael Holdings reported a net loss of $4.8 million, a significant improvement from the $32.4 million loss in the same period last year. This reduction in net loss was largely due to decreased non-cash items and a recovery of receivables. Research and development expenses increased to $3.0 million, reflecting the integration of Cyclo Therapeutics and other consolidated entities. General and administrative expenses also rose to $3.2 million due to the merger and consolidation activities.

Over the first nine months of fiscal 2025, the company recorded a net loss of $18.4 million, down from $29.9 million in the previous year. This decrease was attributed to various financial adjustments related to acquisitions and investments. The company’s cash position was bolstered by the rights offering, ending the quarter with $37.9 million in cash and cash equivalents.

Looking ahead, Rafael Holdings remains focused on advancing its clinical trials and leveraging its enhanced financial position to support the development of new treatment options for rare genetic diseases, as indicated by the management’s strategic outlook.